SCHEMBL22309846

SCHEMBL22309846

COCC1CCN(CCS(C)(=O)=O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
HTR4 Q13639 5/20 0.34
CARM1 Q86X55 2/20 0.33
PRMT6 Q96LA8 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
PMP22 Q01453 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
ADRA2C P18825 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR1D P28221 1/20 0.33
ADRA1B P35368 1/20 0.33
HTR2B P41595 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12820177 0.80 DRD2 (0.34) PRMT6ALDH1A1MAPK1
SCHEMBL4373218 0.80 ALDH1A1 (0.33) TLR9TLR8TLR7ALDH1A1MAPK1
SCHEMBL664708 0.79 ALDH1A1 (0.33) ALDH1A1MAPK1
SCHEMBL4373223 0.79 SYK (0.37) HTTALDH1A1MAPK1
SCHEMBL14951795 0.79 OPRM1 (0.35) TLR9TLR8TLR7HTR4OPRM1
SCHEMBL663338 0.78 ALDH1A1 (0.34) CARM1PRMT6ALDH1A1MAPK1
SCHEMBL16106672 0.77 ALDH1A1 (0.36) HTR4CARM1PRMT6HTTOPRM1
SCHEMBL4375093 0.77 ALDH1A1 (0.35) HTR4CARM1PRMT6CYP2C9ALDH1A1
SCHEMBL666149 0.77 ALDH1A1 (0.35) HTR4CARM1PRMT6CYP2C9ALDH1A1
SCHEMBL13108616 0.77 GNAO1 (0.41) HTR4CHRM4CHRM5CHRM3ADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056559-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) 2023-02-23 US disclosed
EP-3919492-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR Medshine Discovery Inc. (CN) 2021-12-08 EP disclosed
WO-2020156453-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR 南京明德新药研发有限公司 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056559-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR MET, MYC, METAP1 TLR9 1104/4885TLR8 1357/4885TLR7 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.